Skip to content
Menu

BMO Capital Upgrades Ionis Pharmaceuticals to Outperform, Raises Price Target to $66

Benzinga Newsdesk 1 month ago

Analyst RatingsNewsUpgradesPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

BMO Capital analyst David Lebowitz upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Market Perform to Outperform and raises the price target from $54 to $66.

BMO Capital analyst David Lebowitz upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Market Perform to Outperform and raises the price target from $54 to $66.

Read at benzinga.com

← All stock news